Liver toxicity prompts Tango to halt development of solid tumour hopeful

23 May 2024
·
Deals
firstwordpharma.com
Just months after starting a Phase I/II trial of its solid tumour candidate TNG348, Tango Therapeutics said Thursday that it will discontinue development of the USP1 inhibitorUSP1 inhibitor because several participants experienced liver toxicities.
The study enrolled patients with BRCA1/2-mutant and other homologous recombination deficient cancers and dosed the first participant with TNG348 in January.
According to Tango, grade 3/4 liver function abnormalities were observed in patients who remained on the study for more than eight weeks.
“Patient safety is always our first priority and based on emerging data from the TNG348 dose escalation study, we have made the decision to discontinue further development of this molecule due to liver toxicity experienced by patients in the trial,” CEO Barbara Weber said in a statement.
TNG348 was in-licensed in 2020 from Medivir, who was eligible for development and commercial milestones on the programme, as well as royalties.
The company’s portfolio now includes three clinical assets in Phase I/II studies for cancer: TNG908 and TNG462, which both inhibit PRMT5; and TNG260, a highly selective CoREST complex inhibitor.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.